-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
“When the symptoms of dementia appear, the brain is already severely damaged
.
Currently, the diagnosis is too late and there is no opportunity for effective treatment
Molecular signature
The biomarkers that Fisher and his colleagues discovered were based on the measurement of so-called microRNAs in the blood
.
MicroRNAs are molecules with regulatory properties: they affect the production of proteins and are therefore a key process in the metabolism of every organism
Through extensive research on humans, mice, and cell culture, the researchers finally identified three microRNAs related to intellectual performance
.
To this end, they analyzed data on young people, cognitively normal people, and elderly people with mild cognitive impairment (MCI)
Signs of dementia
In the end, various discoveries are pieced together like puzzle pieces: In healthy individuals, the level of microRNA is related to mental health
.
The lower the blood concentration, the better the subject's performance on the cognitive test
Potential targets for treatment
In their studies of mice and cell culture, the researchers also found that these three confirmed microRNAs affect the inflammatory process and "neural plasticity" in the brain, including the ability of neurons to establish connections with each other
.
This shows that these three types of microRNAs are more than just warning signs
Application in daily care
This new marker needs further testing; in addition, the current measurement procedure is too complicated for practical applications: "In further research, our goal is to validate this biomarker clinically
.
In addition, we intend to Develop a simple and instant screening test program," Fischer said
Journal Reference :
Rezaul Islam, Lalit Kaurani et al.
